Oncolytics Biotech Inc.
ONCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22 | $13 | $12 | $10 |
| G&A Expenses | $13 | $0 | $0 | $0 |
| SG&A Expenses | $13 | $12 | $9 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $35 | $25 | $20 | $21 |
| Operating Income | -$35 | -$25 | -$21 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $5 | $2 | -$0 |
| Pre-Tax Income | -$32 | -$20 | -$19 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32 | -$21 | -$19 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.41 | -0.41 | -0.43 | -0.49 |
| % Growth | 0% | 4.7% | 12.2% | – |
| EPS Diluted | -0.41 | -0.41 | -0.43 | -0.49 |
| Weighted Avg Shares Out | 76 | 68 | 58 | 54 |
| Weighted Avg Shares Out Dil | 76 | 68 | 58 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$35 | -$20 | -$19 | -$21 |
| % Margin | – | – | – | – |